MX367364B - Formulaciones de lorazepam de liberación sostenida. - Google Patents
Formulaciones de lorazepam de liberación sostenida.Info
- Publication number
- MX367364B MX367364B MX2015008756A MX2015008756A MX367364B MX 367364 B MX367364 B MX 367364B MX 2015008756 A MX2015008756 A MX 2015008756A MX 2015008756 A MX2015008756 A MX 2015008756A MX 367364 B MX367364 B MX 367364B
- Authority
- MX
- Mexico
- Prior art keywords
- lorazepam
- sustained release
- beads
- release formulations
- composition
- Prior art date
Links
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 title abstract 5
- 229960004391 lorazepam Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000011324 bead Substances 0.000 abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750797P | 2013-01-09 | 2013-01-09 | |
| US201361762833P | 2013-02-08 | 2013-02-08 | |
| PCT/US2014/010854 WO2014110245A1 (en) | 2013-01-09 | 2014-01-09 | Sustained release formulations of lorazepam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008756A MX2015008756A (es) | 2016-03-31 |
| MX367364B true MX367364B (es) | 2019-08-16 |
Family
ID=50064764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008756A MX367364B (es) | 2013-01-09 | 2014-01-09 | Formulaciones de lorazepam de liberación sostenida. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8999393B1 (enExample) |
| EP (1) | EP2943185B1 (enExample) |
| JP (2) | JP6039823B2 (enExample) |
| KR (1) | KR102318274B1 (enExample) |
| CN (1) | CN105209018B (enExample) |
| AU (1) | AU2014205440B2 (enExample) |
| BR (1) | BR112015016304A8 (enExample) |
| CA (1) | CA2897302C (enExample) |
| CL (1) | CL2015001920A1 (enExample) |
| CY (1) | CY1123933T1 (enExample) |
| DK (1) | DK2943185T3 (enExample) |
| ES (1) | ES2856181T3 (enExample) |
| HR (1) | HRP20210236T1 (enExample) |
| HU (1) | HUE054005T2 (enExample) |
| IL (1) | IL239777B (enExample) |
| LT (1) | LT2943185T (enExample) |
| MX (1) | MX367364B (enExample) |
| NZ (1) | NZ710860A (enExample) |
| PE (1) | PE20151432A1 (enExample) |
| PH (1) | PH12015501534B1 (enExample) |
| PL (1) | PL2943185T3 (enExample) |
| PT (1) | PT2943185T (enExample) |
| RS (1) | RS61857B1 (enExample) |
| RU (1) | RU2678324C2 (enExample) |
| SG (1) | SG11201505349RA (enExample) |
| SI (1) | SI2943185T1 (enExample) |
| SM (1) | SMT202100091T1 (enExample) |
| UA (1) | UA117233C2 (enExample) |
| WO (1) | WO2014110245A1 (enExample) |
| ZA (1) | ZA201505082B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019039836A2 (ko) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
| RU2020117757A (ru) * | 2017-11-01 | 2021-11-29 | Эджмонт Фармасьютикалс, Ллк Траст | Оральные фармацевтические композиции лоразепама, устойчивые к спирту |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL298071A (enExample) | 1963-06-04 | |||
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3786813A (en) | 1972-12-27 | 1974-01-22 | Alza Corp | Drug delivery device with self actuated mechanism for retaining device in selected area |
| DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| US4361545A (en) | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| FR2473884B1 (fr) * | 1980-01-21 | 1985-06-07 | Wellcome Found | Associations d'une halogeno-propiophenone et d'une diazepine, medicaments tranquillisants contenant de telles associations, et leur preparation |
| WO1985004100A1 (en) * | 1984-03-21 | 1985-09-26 | American Home Products Corporation | Sustained release pharmaceutical capsules |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4624847A (en) | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
| IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| US5273758A (en) | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
| US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| CA2144077C (en) | 1992-09-18 | 2005-05-24 | Kazuhiro Sako | Hydrogel-type sustained-release preparation |
| US5871776A (en) | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| US6348469B1 (en) | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
| DE69941212D1 (de) * | 1998-03-23 | 2009-09-17 | Gen Mills Inc | Verkapselung von komponenten in essbaren produkten |
| US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| WO2000059481A1 (en) * | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| AU2141202A (en) | 2000-12-05 | 2002-06-18 | Alexander Macgregor | Hydrostatic delivery system for controlled delivery of agent |
| EP1250937B1 (en) | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| JP4426286B2 (ja) | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US6703045B2 (en) | 2001-08-21 | 2004-03-09 | Council Of Scientific & Industrial Research | Composition and method for maintaining blood glucose level |
| US20030050620A1 (en) * | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
| US6663888B2 (en) | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
| KR100540035B1 (ko) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| US20040028729A1 (en) | 2002-04-29 | 2004-02-12 | Shojaei Amir H. | Pharmaceutical formulations with improved bioavailability |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| US20050031688A1 (en) * | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| WO2005027877A1 (en) * | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| AR046410A1 (es) * | 2003-09-18 | 2005-12-07 | Cephalon Inc | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
| JP2008530134A (ja) * | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤 |
| US9205047B2 (en) * | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US20070071819A1 (en) | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
| WO2007010369A2 (en) | 2005-07-22 | 2007-01-25 | Emcure Pharmaceuticals Limited | Sustained release formulation of alprazolam |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CA2635594A1 (en) * | 2005-12-30 | 2007-07-12 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
| US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| BRPI0716196A2 (pt) * | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| EP2097067A2 (en) | 2006-12-05 | 2009-09-09 | University Of The Witwatersrand, Johannesburg | A heterogeneously configured multiparticulate gastrointestinal drug delivery system |
| WO2009137067A1 (en) * | 2008-05-08 | 2009-11-12 | Supernus Pharmaceuticals Inc. | Controlled release formulations of alprazolam |
| US20110217371A1 (en) | 2008-11-10 | 2011-09-08 | Amorepacific Corporation | Controlled-release microparticles and method of preparing same |
| US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2014
- 2014-01-08 US US14/150,375 patent/US8999393B1/en active Active
- 2014-01-09 ES ES14702977T patent/ES2856181T3/es active Active
- 2014-01-09 BR BR112015016304A patent/BR112015016304A8/pt not_active Application Discontinuation
- 2014-01-09 EP EP14702977.1A patent/EP2943185B1/en active Active
- 2014-01-09 RS RS20210047A patent/RS61857B1/sr unknown
- 2014-01-09 SM SM20210091T patent/SMT202100091T1/it unknown
- 2014-01-09 CN CN201480012336.8A patent/CN105209018B/zh active Active
- 2014-01-09 KR KR1020157020977A patent/KR102318274B1/ko active Active
- 2014-01-09 HU HUE14702977A patent/HUE054005T2/hu unknown
- 2014-01-09 HR HRP20210236TT patent/HRP20210236T1/hr unknown
- 2014-01-09 AU AU2014205440A patent/AU2014205440B2/en active Active
- 2014-01-09 DK DK14702977.1T patent/DK2943185T3/da active
- 2014-01-09 RU RU2015128915A patent/RU2678324C2/ru active
- 2014-01-09 PE PE2015001248A patent/PE20151432A1/es active IP Right Grant
- 2014-01-09 SI SI201431768T patent/SI2943185T1/sl unknown
- 2014-01-09 JP JP2015551869A patent/JP6039823B2/ja active Active
- 2014-01-09 MX MX2015008756A patent/MX367364B/es active IP Right Grant
- 2014-01-09 WO PCT/US2014/010854 patent/WO2014110245A1/en not_active Ceased
- 2014-01-09 SG SG11201505349RA patent/SG11201505349RA/en unknown
- 2014-01-09 UA UAA201507784A patent/UA117233C2/uk unknown
- 2014-01-09 CA CA2897302A patent/CA2897302C/en active Active
- 2014-01-09 NZ NZ710860A patent/NZ710860A/en unknown
- 2014-01-09 PT PT147029771T patent/PT2943185T/pt unknown
- 2014-01-09 PL PL14702977T patent/PL2943185T3/pl unknown
- 2014-01-09 LT LTEP14702977.1T patent/LT2943185T/lt unknown
-
2015
- 2015-03-04 US US14/639,027 patent/US20150174078A1/en not_active Abandoned
- 2015-07-05 IL IL239777A patent/IL239777B/en active IP Right Grant
- 2015-07-06 CL CL2015001920A patent/CL2015001920A1/es unknown
- 2015-07-07 PH PH12015501534A patent/PH12015501534B1/en unknown
- 2015-07-15 ZA ZA2015/05082A patent/ZA201505082B/en unknown
- 2015-12-23 US US14/757,465 patent/US20160228378A1/en not_active Abandoned
-
2016
- 2016-11-04 JP JP2016216160A patent/JP2017019880A/ja not_active Abandoned
-
2021
- 2021-01-21 CY CY20211100046T patent/CY1123933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272423A (en) | Administration, use and therapeutic applications of the CRISPR-CAS system and preparations for targeting disorders and diseases by using particulate delivery components | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| EP3043824A4 (en) | Modified therapeutic agents and compositions thereof | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IN2012DE00912A (enExample) | ||
| IL245483A0 (en) | Fibroblast growth factor receptor 3 (fgfr3) compounds and medical uses | |
| AU201613322S (en) | A Compliance Monitor for a Medicament Inhaler | |
| BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
| ME03656B (me) | Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primjene i postupci njihove upotrebe | |
| PH12015501534A1 (en) | Sustained release formulations of lorazepam | |
| IL245015A0 (en) | Medicinal composition containing icotinib for topical treatment of the skin and its use | |
| PL3041837T3 (pl) | Kryształ o specyficznym pokroju kryształu i kompozycja farmaceutyczna zawierająca ten kryształ jako składnik czynny | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| MX2015008757A (es) | Formulaciones de lorazepam de liberacion controlada. | |
| SG10201810093PA (en) | Pharmaceutical composition for external use | |
| EP2968011A4 (en) | Compositions and methods for delivering therapeutic and imaging agents to the sinuses and middle ear | |
| TWD166399S (zh) | 飲料分配器之部分 | |
| AR094391A1 (es) | Formulaciones de lorazepam de liberación sostenida | |
| UA59396U (ru) | Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью | |
| AU367396S (en) | A compliance monitor for a medicament inhaler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |